Youssef M. K. Farag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Youssef M. K. Farag has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Ajay K. Singh
Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
9 shared publications - Alan F Almeida
Hinduja Hospital, Mumbai, India
2 shared publications B.V. Mittal
2 shared publications- Bharat V. Shah
Department of Nephrology, Institute of Renal Sciences, Global Hospital Parel-12, Mumbai, Maharashtra, India
2 shared publications - Bharati V Mittal
Renal Division, Brigham & Women’s Hospital & Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
2 shared publications Bharati V. Mittal
Renal Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis
Introduction: Anaemia is a common complication affecting ∼42% patients with chronic kidney disease (CKD) stages 3–5 at 1 year after diagnosis and ∼67% at 5 years, with prevalence increasing as estimated glomerular filtration rate (eGFR) decreases. Despite the fact that anaemia is associated with CKD progression, adverse cardiovascular (CV) events and premature mortality in patients with CKD, management of these patients remains suboptimal. The nonsteroidal mineralocorticoid receptor antagonist finerenone demonstrated significant cardiorenal benefits in patients with CKD and type 2 diabetes (T2D) in FIDELITY (a prespecified pooled analysis of the phase III FIDELIO-DKD and FIGARO-DKD trials). However, the effect of anaemia on CV and kidney outcomes in patients receiving finerenone has not been established. Purpose: This post hoc analysis investigated the treatment effects and safety of finerenone vs placebo in patients categorised by baseline anaemia status. Methods: Eligible patients with CKD (urine albumin-to-creatinine ratio [UACR] ≥30–<300 mg/g and eGFR ≥25–≤90 ml/min/1.73 m² or UACR ≥300–≤5000 mg/g and eGFR ≥25 ml/min/1.73 m²) and T2D, and on optimised renin–angiotensin system inhibitor were randomised 1:1 to finerenone or placebo. Anaemia was defined using the World Health Organization criteria: serum haemoglobin levels <13 g/dl (male) or <12 g/dl (female) or treatment with an erythropoiesis-stimulating agent at baseline. Key outcomes analysed by baseline anaemia status included a CV composite (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for heart failure [HHF]) and kidney composite (kidney failure, sustained eGFR decrease ≥57%, or kidney-related death), HHF, and all-cause mortality. Safety outcomes were assessed by treatment-emergent adverse events. Results: Of 13,007 patients, 4293 (33.0%) had anaemia at baseline. The risk reduction on the CV composite outcome was nominally significant with finerenone vs placebo in patients with anaemia at baseline but not in those without (p-value for interaction=0.04; Figure 1). Finerenone also reduced the risk of the kidney composite outcome vs placebo, with no heterogeneity between the treatment groups and across the anaemia subgroups (Figure 1). In addition, finerenone was associated with a reduced risk of all-cause mortality and HHF outcomes vs placebo, irrespective of baseline anaemia status (Figure 1). Incidence of treatment emergent hyperkalaemia was higher in patients with anaemia at baseline in both treatment arms (21.2% finerenone vs 11.5% placebo) compared to those without anaemia (10.5% finerenone vs 4.6% placebo). Conclusions: In patients with CKD and T2D, anaemia was found to be a modifier to the effect of finerenone on the CV composite outcome. There was no heterogeneity of treatment effects with finerenone vs placebo, by anaemia at baseline, on kidney composite outcome, all-cause mortality and HHF.
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessEffect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis
Introduction: Anaemia is a common complication affecting ∼42% patients with chronic kidney disease (CKD) stages 3–5 at 1 year after diagnosis and ∼67% at 5 years, with prevalence increasing as estimated glomerular filtration rate (eGFR) decreases. Despite the fact that anaemia is associated with CKD progression, adverse cardiovascular (CV) events and premature mortality in patients with CKD, management of these patients remains suboptimal. The nonsteroidal mineralocorticoid receptor antagonist finerenone demonstrated significant cardiorenal benefits in patients with CKD and type 2 diabetes (T2D) in FIDELITY (a prespecified pooled analysis of the phase III FIDELIO-DKD and FIGARO-DKD trials). However, the effect of anaemia on CV and kidney outcomes in patients receiving finerenone has not been established. Purpose: This post hoc analysis investigated the treatment effects and safety of finerenone vs placebo in patients categorised by baseline anaemia status. Methods: Eligible patients with CKD (urine albumin-to-creatinine ratio [UACR] ≥30–<300 mg/g and eGFR ≥25–≤90 ml/min/1.73 m² or UACR ≥300–≤5000 mg/g and eGFR ≥25 ml/min/1.73 m²) and T2D, and on optimised renin–angiotensin system inhibitor were randomised 1:1 to finerenone or placebo. Anaemia was defined using the World Health Organization criteria: serum haemoglobin levels <13 g/dl (male) or <12 g/dl (female) or treatment with an erythropoiesis-stimulating agent at baseline. Key outcomes analysed by baseline anaemia status included a CV composite (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for heart failure [HHF]) and kidney composite (kidney failure, sustained eGFR decrease ≥57%, or kidney-related death), HHF, and all-cause mortality. Safety outcomes were assessed by treatment-emergent adverse events. Results: Of 13,007 patients, 4293 (33.0%) had anaemia at baseline. The risk reduction on the CV composite outcome was nominally significant with finerenone vs placebo in patients with anaemia at baseline but not in those without (p-value for interaction=0.04; Figure 1). Finerenone also reduced the risk of the kidney composite outcome vs placebo, with no heterogeneity between the treatment groups and across the anaemia subgroups (Figure 1). In addition, finerenone was associated with a reduced risk of all-cause mortality and HHF outcomes vs placebo, irrespective of baseline anaemia status (Figure 1). Incidence of treatment emergent hyperkalaemia was higher in patients with anaemia at baseline in both treatment arms (21.2% finerenone vs 11.5% placebo) compared to those without anaemia (10.5% finerenone vs 4.6% placebo). Conclusions: In patients with CKD and T2D, anaemia was found to be a modifier to the effect of finerenone on the CV composite outcome. There was no heterogeneity of treatment effects with finerenone vs placebo, by anaemia at baseline, on kidney composite outcome, all-cause mortality and HHF.
- Open Access
- 7 March 2022
- Published by Elsevier in Kidney Medicine
- Vol. 4 (4) , 100439
Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
- 7 March 2022
- Published by Elsevier in Kidney Medicine
- Vol. 4 (4) , 100439
Open AccessPatient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
- Open Access
- 1 January 2016
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 22 (6) , 423-427
Thromboembolic events in patients with inflammatory bowel disease
Background/Aims: Inflammatory bowel disease (ulcerative colitis and Crohn's disease) is characterized by a chronic inflammatory condition, and is accompanied by abnormalities in coagulation and a hyper-coagulable state. This study was conducted to examine the risk factors for developing Thromboembolic Events in Inflammatory Bowel Disease (IBD) in a population with prevalent consanguinity. Patients and Methods: Patients with a definitive diagnosis of IBD who were seen in the gastroenterology clinic of King Khalid University Hospital (Riyadh, Saudi Arabia) from 2010- to 2012, were asked to participate in this prospective cohort study, and were followed for one 1 year. Data was collected using specifically designed case report forms (CRF) by trained research personnel. Results: A total of 100 Saudi patients with IBD were studied. There were 51 (51%) women and the mean ± standard deviation (SD) age of the group was 31.24 ± 10.78 years. Those with Crohn's disease constituted 72% of the patients, and 28% had ulcerative colitis. Eight patients (8%) had at least one Thrombotic Event ([six deep venous thrombosis (DVT), and two pulmonary embolism (PE)]. Family history of deep venous thrombosis was present in 5%, and family history of pulmonary embolism (PE) in 4% of the patients. After adjusting for age and gender, a family history of Thrombotic event was identified as to be the only statistically significant predictor of thrombosis in IBD patients (RR = 9.22, 95% CI: 2.10-–40.43). Conclusion: In a population with high consanguinity, Thromboembolic events (DVT and PE) had a prevalence of 8% among IBD patients, positive family history of pulmonary embolism was a predictor of thrombosis. Further studies are needed to explore the role of genetic factors in this population.
- 1 January 2016
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 22 (6) , 423-427
Open AccessThromboembolic events in patients with inflammatory bowel disease
Background/Aims: Inflammatory bowel disease (ulcerative colitis and Crohn's disease) is characterized by a chronic inflammatory condition, and is accompanied by abnormalities in coagulation and a hyper-coagulable state. This study was conducted to examine the risk factors for developing Thromboembolic Events in Inflammatory Bowel Disease (IBD) in a population with prevalent consanguinity. Patients and Methods: Patients with a definitive diagnosis of IBD who were seen in the gastroenterology clinic of King Khalid University Hospital (Riyadh, Saudi Arabia) from 2010- to 2012, were asked to participate in this prospective cohort study, and were followed for one 1 year. Data was collected using specifically designed case report forms (CRF) by trained research personnel. Results: A total of 100 Saudi patients with IBD were studied. There were 51 (51%) women and the mean ± standard deviation (SD) age of the group was 31.24 ± 10.78 years. Those with Crohn's disease constituted 72% of the patients, and 28% had ulcerative colitis. Eight patients (8%) had at least one Thrombotic Event ([six deep venous thrombosis (DVT), and two pulmonary embolism (PE)]. Family history of deep venous thrombosis was present in 5%, and family history of pulmonary embolism (PE) in 4% of the patients. After adjusting for age and gender, a family history of Thrombotic event was identified as to be the only statistically significant predictor of thrombosis in IBD patients (RR = 9.22, 95% CI: 2.10-–40.43). Conclusion: In a population with high consanguinity, Thromboembolic events (DVT and PE) had a prevalence of 8% among IBD patients, positive family history of pulmonary embolism was a predictor of thrombosis. Further studies are needed to explore the role of genetic factors in this population.
- Open Access
- 6 March 2014
- Published by Springer Nature in BMC Nephrology
- Vol. 15 (1) , 42
Burden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of Kidney Disease) study
Background: Hypertension (HTN) is one of the major causes of cardiovascular morbidity and mortality. The objective of the study was to investigate the burden and predictors of HTN in India.Methods: 6120 subjects participated in the Screening and Early Evaluation of Kidney disease (SEEK), a community-based screening program in 53 camps in 13 representative geographic locations in India. Of these, 5929 had recorded blood pressure (BP) measurements. Potential predictors of HTN were collected using a structured questionnaire for SEEK study.Results: HTN was observed in 43.5% of our cohort. After adjusting for center variation (p < 0.0001), predictors of a higher prevalence of HTN were older age ≥40 years (p < 0.0001), BMI of ≥ 23 Kg/M2(p < 0.0004), larger waist circumference (p < 0.0001), working in sedentary occupation (p < 0.0001), having diabetes mellitus (p < 0.0001), having proteinuria (p < 0.0016), and increased serum creatinine (p < 0.0001). High school/some college education (p = 0.0016), versus less than 9th grade education, was related with lower prevalence of HTN. Of note, proteinuria and CKD were observed in 19% and 23.5% of HTN subjects. About half (54%) of the hypertensive subjects were aware of their hypertension status.Conclusions: HTN was common in this cohort from India. Older age, BMI ≥ 23 Kg/M2, waist circumference, sedentary occupation, education less, diabetes mellitus, presence of proteinuria, and raised serum creatinine were significant predictors of hypertension. Our data suggest that HTN is a major public health problem in India with low awareness, and requires aggressive community-based screening and education to improve health.
- 6 March 2014
- Published by Springer Nature in BMC Nephrology
- Vol. 15 (1) , 42
Open AccessBurden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of Kidney Disease) study
Background: Hypertension (HTN) is one of the major causes of cardiovascular morbidity and mortality. The objective of the study was to investigate the burden and predictors of HTN in India.Methods: 6120 subjects participated in the Screening and Early Evaluation of Kidney disease (SEEK), a community-based screening program in 53 camps in 13 representative geographic locations in India. Of these, 5929 had recorded blood pressure (BP) measurements. Potential predictors of HTN were collected using a structured questionnaire for SEEK study.Results: HTN was observed in 43.5% of our cohort. After adjusting for center variation (p < 0.0001), predictors of a higher prevalence of HTN were older age ≥40 years (p < 0.0001), BMI of ≥ 23 Kg/M2(p < 0.0004), larger waist circumference (p < 0.0001), working in sedentary occupation (p < 0.0001), having diabetes mellitus (p < 0.0001), having proteinuria (p < 0.0016), and increased serum creatinine (p < 0.0001). High school/some college education (p = 0.0016), versus less than 9th grade education, was related with lower prevalence of HTN. Of note, proteinuria and CKD were observed in 19% and 23.5% of HTN subjects. About half (54%) of the hypertensive subjects were aware of their hypertension status.Conclusions: HTN was common in this cohort from India. Older age, BMI ≥ 23 Kg/M2, waist circumference, sedentary occupation, education less, diabetes mellitus, presence of proteinuria, and raised serum creatinine were significant predictors of hypertension. Our data suggest that HTN is a major public health problem in India with low awareness, and requires aggressive community-based screening and education to improve health.
- Top Cited PapersOpen Access
- 28 May 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 114
Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney Disease) study
There is a rising incidence of chronic kidney disease that is likely to pose major problems for both healthcare and the economy in future years. In India, it has been recently estimated that the age-adjusted incidence rate of ESRD to be 229 per million population (pmp), and >100,000 new patients enter renal replacement programs annually. We cross-sectionally screened 6120 Indian subjects from 13 academic and private medical centers all over India. We obtained personal and medical history data through a specifically designed questionnaire. Blood and urine samples were collected. The total cohort included in this analysis is 5588 subjects. The mean ± SD age of all participants was 45.22 ± 15.2 years (range 18–98 years) and 55.1% of them were males and 44.9% were females. The overall prevalence of CKD in the SEEK-India cohort was 17.2% with a mean eGFR of 84.27 ± 76.46 versus 116.94 ± 44.65 mL/min/1.73 m2 in non-CKD group while 79.5% in the CKD group had proteinuria. Prevalence of CKD stages 1, 2, 3, 4 and 5 was 7%, 4.3%, 4.3%, 0.8% and 0.8%, respectively. The prevalence of CKD was observed to be 17.2% with ~6% have CKD stage 3 or worse. CKD risk factors were similar to those reported in earlier studies. It should be stressed to all primary care physicians taking care of hypertensive and diabetic patients to screen for early kidney damage. Early intervention may retard the progression of kidney disease. Planning for the preventive health policies and allocation of more resources for the treatment of CKD/ESRD patients are imperative in India.
- 28 May 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 114
Top Cited PapersOpen AccessEpidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney Disease) study
There is a rising incidence of chronic kidney disease that is likely to pose major problems for both healthcare and the economy in future years. In India, it has been recently estimated that the age-adjusted incidence rate of ESRD to be 229 per million population (pmp), and >100,000 new patients enter renal replacement programs annually. We cross-sectionally screened 6120 Indian subjects from 13 academic and private medical centers all over India. We obtained personal and medical history data through a specifically designed questionnaire. Blood and urine samples were collected. The total cohort included in this analysis is 5588 subjects. The mean ± SD age of all participants was 45.22 ± 15.2 years (range 18–98 years) and 55.1% of them were males and 44.9% were females. The overall prevalence of CKD in the SEEK-India cohort was 17.2% with a mean eGFR of 84.27 ± 76.46 versus 116.94 ± 44.65 mL/min/1.73 m2 in non-CKD group while 79.5% in the CKD group had proteinuria. Prevalence of CKD stages 1, 2, 3, 4 and 5 was 7%, 4.3%, 4.3%, 0.8% and 0.8%, respectively. The prevalence of CKD was observed to be 17.2% with ~6% have CKD stage 3 or worse. CKD risk factors were similar to those reported in earlier studies. It should be stressed to all primary care physicians taking care of hypertensive and diabetic patients to screen for early kidney damage. Early intervention may retard the progression of kidney disease. Planning for the preventive health policies and allocation of more resources for the treatment of CKD/ESRD patients are imperative in India.
- Open Access
- 17 April 2013
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 8 (3) , 287-296
Predictors of diabetic nephropathy
Diabetic nephropathy (DN) is a leading cause of morbidity and mortality in diabetic patients representing a huge health and economic burden. Alarming recent data described diabetes as an unprecedented worldwide epidemic, with a prevalence of ∼6.4% of the world population in 2010, while the prevalence of CKD among diabetics was approximately 40%. With a clinical field hungry for novel markers predicting DN, several clinical and laboratory markers were identified lately with the promise of reliable DN prediction. Among those are age, gender, hypertension, smoking, sex hormones and anemia. In addition, eccentric left ventricular geometric patterns, detected by echocardiography, and renal hypertrophy, revealed by ultrasonography, are promising new markers predicting DN development. Serum and urinary markers are still invaluable elements, including serum uric acid, microalbuminuria, macroalbuminuria, urinary liver-type fatty acid-binding protein (u-LFABP), and urinary nephrin. Moreover, studies have illustrated a tight relationship between obstructive sleep apnea and the development of DN. The purpose of this review is to present the latest advances in identifying promising predictors to DN, which will help guide the future research questions in this field. Aiming at limiting this paramount threat, further efforts are necessary to identify and control independent modifiable risk factors, while developing an integrative algorithm for utilization in DN future screening programs.
- 17 April 2013
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 8 (3) , 287-296
Open AccessPredictors of diabetic nephropathy
Diabetic nephropathy (DN) is a leading cause of morbidity and mortality in diabetic patients representing a huge health and economic burden. Alarming recent data described diabetes as an unprecedented worldwide epidemic, with a prevalence of ∼6.4% of the world population in 2010, while the prevalence of CKD among diabetics was approximately 40%. With a clinical field hungry for novel markers predicting DN, several clinical and laboratory markers were identified lately with the promise of reliable DN prediction. Among those are age, gender, hypertension, smoking, sex hormones and anemia. In addition, eccentric left ventricular geometric patterns, detected by echocardiography, and renal hypertrophy, revealed by ultrasonography, are promising new markers predicting DN development. Serum and urinary markers are still invaluable elements, including serum uric acid, microalbuminuria, macroalbuminuria, urinary liver-type fatty acid-binding protein (u-LFABP), and urinary nephrin. Moreover, studies have illustrated a tight relationship between obstructive sleep apnea and the development of DN. The purpose of this review is to present the latest advances in identifying promising predictors to DN, which will help guide the future research questions in this field. Aiming at limiting this paramount threat, further efforts are necessary to identify and control independent modifiable risk factors, while developing an integrative algorithm for utilization in DN future screening programs.
- 24 December 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (6) , 927-931
Renal impairment in children with posterior urethral valves
Posterior urethral valves (PUV) are a common cause of end-stage renal failure in childhood. Our aim was to describe a cohort of patients with PUV and to investigate the predictors of renal impairment.
- 24 December 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (6) , 927-931
Renal impairment in children with posterior urethral valves
Posterior urethral valves (PUV) are a common cause of end-stage renal failure in childhood. Our aim was to describe a cohort of patients with PUV and to investigate the predictors of renal impairment.
- Open Access
- 28 November 2012
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 121 (3-4) , c120-c123
Chronic Kidney Disease in the Arab World: A Call for Action
Chronic kidney disease (CKD) is an emerging non-communicable disease worldwide. The Arab countries have a high prevalence of CKD risk factors, e.g. diabetes, obesity and hypertension. Unfortunately, the magnitude of CKD in the Arab world has not been studied well. This review presents the current data on CKD in the Arab world and proposes a call for action to address this rising epidemic.
- 28 November 2012
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 121 (3-4) , c120-c123
Open AccessChronic Kidney Disease in the Arab World: A Call for Action
Chronic kidney disease (CKD) is an emerging non-communicable disease worldwide. The Arab countries have a high prevalence of CKD risk factors, e.g. diabetes, obesity and hypertension. Unfortunately, the magnitude of CKD in the Arab world has not been studied well. This review presents the current data on CKD in the Arab world and proposes a call for action to address this rising epidemic.
- 11 April 2012
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 18 (5) , 453-461
Modulation of Platelet Activation in Chronic Kidney Disease Patients on Erythropoiesis-Stimulating Agents
Background: Clinical trials demonstrate either no benefit or increased risk of cardiovascular events and mortality in patients with chronic kidney disease (CKD) targeted for higher hemoglobin levels, who are treated with erythropoiesis-stimulating agents (ESAs). The mechanism underlying this observation remains unexplained. Methods and Results: We assessed platelet activation by measuring soluble P-selectin (sPsel), CD40 ligand (CD40L), and circulating microparticles (CMP) in patients with CKD. Higher hemoglobin levels were associated with increased Psel levels in patients on ESAs but not in ESA-naïve anemic and nonanemic patients. Psel positively correlated with CMP and CD40L in both anemic and nonanemic patients. Multivariate linear regression analysis revealed an association between increased Psel levels and hemoglobin concentration in patients receiving ESAs. Conclusions: Anemic CKD patients on ESAs demonstrate increased levels of markers of platelet activation. These observations suggest a potentially complex interplay between platelet activation, impaired kidney function, and treatment of CKD anemia with ESAs.
- 11 April 2012
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 18 (5) , 453-461
Modulation of Platelet Activation in Chronic Kidney Disease Patients on Erythropoiesis-Stimulating Agents
Background: Clinical trials demonstrate either no benefit or increased risk of cardiovascular events and mortality in patients with chronic kidney disease (CKD) targeted for higher hemoglobin levels, who are treated with erythropoiesis-stimulating agents (ESAs). The mechanism underlying this observation remains unexplained. Methods and Results: We assessed platelet activation by measuring soluble P-selectin (sPsel), CD40 ligand (CD40L), and circulating microparticles (CMP) in patients with CKD. Higher hemoglobin levels were associated with increased Psel levels in patients on ESAs but not in ESA-naïve anemic and nonanemic patients. Psel positively correlated with CMP and CD40L in both anemic and nonanemic patients. Multivariate linear regression analysis revealed an association between increased Psel levels and hemoglobin concentration in patients receiving ESAs. Conclusions: Anemic CKD patients on ESAs demonstrate increased levels of markers of platelet activation. These observations suggest a potentially complex interplay between platelet activation, impaired kidney function, and treatment of CKD anemia with ESAs.
- Open Access
- 1 November 2011
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 119 (4) , c317-c323
Diabetic Nephropathy in the Arab Gulf Countries
While the prevalence of diabetes mellitus is increasing worldwide, one third of the diabetic patients will eventually develop chronic kidney disease. The aim of this review is to present the available data on diabetic nephropathy and its complications in the Arab Gulf countries. This will eventually help to raise the awareness of both government and healthcare systems towards the substantial value of prevention, early detection as well as proper management of both diabetes mellitus and chronic kidney disease. This could be achieved by funding large-scale longitudinal studies, improving training programs (both research and clinical) and increasing the role of media in fighting this epidemic.
- 1 November 2011
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 119 (4) , c317-c323
Open AccessDiabetic Nephropathy in the Arab Gulf Countries
While the prevalence of diabetes mellitus is increasing worldwide, one third of the diabetic patients will eventually develop chronic kidney disease. The aim of this review is to present the available data on diabetic nephropathy and its complications in the Arab Gulf countries. This will eventually help to raise the awareness of both government and healthcare systems towards the substantial value of prevention, early detection as well as proper management of both diabetes mellitus and chronic kidney disease. This could be achieved by funding large-scale longitudinal studies, improving training programs (both research and clinical) and increasing the role of media in fighting this epidemic.